✨ Free AI Report
PolyPeptide Group AG: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research PolyPeptide Group AG
Company Research

PolyPeptide Group AG: Business Overview, Financials & Competitive Analysis

PolyPeptide Group is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. The company serves a fast-growing market with a bro...

Analyst-debate audio for PolyPeptide Group AG

AskCyborg analysts argue the bull and bear cases for PolyPeptide Group AG across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Specialized CDMO with high exposure to GLP-1 and metabolic disease therapeutics benefits from structural market tailwinds in...

Read the full analyst-debate transcript →
Industry Pharmaceutical Contract Development & Manufacturing Organization (CDMO) - Peptide & Oligonucleotide Specialization
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest PolyPeptide Group AG Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

PolyPeptide Group AG Overview

Pro stress-test →

PolyPeptide Group is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. The company serves a fast-growing market with a broad portfolio offering products and services from pre-clinical through commercial stages, with large exposure to metabolic diseases including GLP-1.

Strategic Profile

Pro stress-test →

Established in 1952, PolyPeptide operates a global network of six GMP-certified facilities in Europe, the U.S. and India. The company is positioned as a specialized player in the high-growth peptide therapeutics market, benefiting from strong demand trends in novel drug development, particularly in metabolic disease treatments like GLP-1 agonists.

Competitive Landscape

Pro stress-test →

PolyPeptide competes in the specialized peptide CDMO segment alongside larger diversified CDMOs like Catalent and specialized players like Lonza. The company differentiates through focused expertise in peptide manufacturing and exposure to high-growth therapeutic areas, particularly metabolic diseases. Competition centers on manufacturing capacity, regulatory expertise, and ability to support drug development across clinical stages.

Industry Context

PolyPeptide Group AG operates in Pharmaceutical Contract Development & Manufacturing Organization (CDMO) - Peptide & Oligonucleotide Specialization.

Key facts

Founded: 1952 · Headquarters: Switzerland

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on PolyPeptide Group AG.

  • Strong market positioning in peptide-based active pharmaceutical ingredients for a fast-growing therapeutic area
  • Significant exposure to GLP-1 and metabolic disease therapeutics, aligning with major pharmaceutical development trends
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • September 2025Successful ramp-up of Belgian facility with revised full-year guidance toward upper end of range
  • 2025Appointment of Raoul Bernhardt as Chief Manufacturing and Supply Chain Officer
  • +1 moreTrack every material event for PolyPeptide Group AG as it happens. Explore monitoring →
Get alerted when PolyPeptide Group AG has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Peptide CDMO ServicesLarge diversified CDMO with peptide capabilities→Peptide and Small Molecule CDMOMajor global CDMO with broad manufacturing portfolio→Peptide CDMO ServicesCell and gene therapy CDMO with biosafety testing→

Compare PolyPeptide Group AG with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

PolyPeptide Group AG operates in Pharmaceutical Contract Development & Manufacturing Organization (CDMO) - Peptide & Oligonucleotide Specialization. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Contract Development & Manufacturing Organization (CDMO) - Peptide & Oligonucleotide Specialization research →
NEW · MCP server

Ask your AI assistant about PolyPeptide Group AG

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare PolyPeptide Group AG and its top competitor on Cyborg Score”
“What did PolyPeptide Group AG do this quarter?”
“Is PolyPeptide Group AG a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does PolyPeptide Group AG do?+
PolyPeptide Group is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide- and oligonucleotide-based active pharmaceutical ingredients. The company serves a fast-growing market with a bro...
What is PolyPeptide Group AG's Cyborg Score?+
PolyPeptide Group AG has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are PolyPeptide Group AG's main competitors?+
Named competitors include Peptide CDMO Services, Peptide and Small Molecule CDMO, Peptide CDMO Services. The full competitive landscape is in the AskCyborg report.
How can I get the full PolyPeptide Group AG research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the PolyPeptide Group AG research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track PolyPeptide Group AG over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.